Zepatier, elbasvir/grazoprevir (MK-5172/MK-8742)
ZEPATIER is a prescription medication. Only your health care provider can decide whether ZEPATIER is right for you.
If eligible, follow these steps to save on each qualifying prescription of ZEPATIER:
•If your doctor thinks that ZEPATIER is right for you, he or she will write a prescription for ZEPATIER.
•Patient must pay the first $5 on each prescription (up to 28 tablets per prescription). Savings are limited to the amount of the patient's actual out-of-pocket cost over $5 on each qualifying prescription, up to a maximum benefit of 25% of the catalog price of ZEPATIER (as set by the manufacturer at the time of purchase) per prescription. Coupon savings may not exceed the patient's actual out-of-pocket cost. Coupon may be redeemed on qualifying prescriptions (up to 28 tablets per prescription) for up to 112 tablets of ZEPATIER in total prior to the coupon expiration date.
•Review the Terms and Conditions below and then click on the "Activate & Print a New Coupon" button below and follow the activation instructions.
•Print the coupon.
•Present the activated coupon and your insurance card with a valid signed prescription at any participating eligible retail or mail-order pharmacy (certain restrictions apply).
•If you are unable to redeem the coupon at your eligible retail or mail-order pharmacy, please keep your receipt and call McKesson Corporation at 877-264-2454 within 30 days of purchase to request a Direct Member Reimbursement (DMR) form. Please note: Not all patients will be eligible for Direct Member Reimbursement. Merck may discontinue Direct Member Reimbursement at any time without notice.
•If you lose the coupon, please visit zepatier.com to obtain a replacement coupon. Regardless of the number of replacement coupons received, the coupon offer is limited to savings on qualifying prescriptions for up to 112 tablets of ZEPATIER in total before the expiration date.
•Not all patients are eligible to use the coupon. Please see Coupon Terms and Conditions.
Please note: The same coupon offer may be available in different forms. For example, you may receive the coupon from your doctor, or you may print it yourself from the product Web site. Regardless of how many coupons you receive or print, you may only use the coupon to save on your out-of-pocket costs on qualifying prescriptions (up to 28 tablets per prescription) for up to 112 tablets of ZEPATIER in total before the expiration date printed on the coupon.
ZEPATIER Rx
Viral infections  Only 4 drugs may be compared at once
Remove Selected
Compare Selected
Generic Name and Formulations:
Elbasvir, grazoprevir 50mg/100mg; tabs.
Company:
Merck & Co., Inc.
 
Select therapeutic use: Viral infections
Indications for ZEPATIER:
Chronic HCV genotypes 1 or 4 infection with or without ribavirin (RBV).

Adult:
≥18yrs: 1 tab once daily. Genotype 1a: treatment-naive or PegIFN/RBV-experienced without baseline NS5A polymorphisms: treat for 12 weeks; with baseline NS5A polymorphisms: take with RBV for 16 weeks. Genotype 1b: treatment-naive or PegIFN/RBV-experienced: treat for 12 weeks. Genotype 1a or 1b: PegIFN/RBV/HCV NS3/4A protease inhibitor (PI)-experienced: take with RBV for 12 weeks. Genotype 4: treatment-naive: treat for 12 weeks; if PegIFN/RBV-experienced: take with RBV for 16 weeks. HCV/HIV-1 co-infected with or without cirrhosis, renal impairment including hemodialysis: follow same dosage regimen. See full labeling.

Children:
<18yrs: not established.

Contraindications:
Moderate or severe hepatic impairment. Concomitant atazanavir, carbamazepine, cyclosporine, darunavir, efavirenz, lopinavir, phenytoin, rifampin, saquinavir, St. John’s wort, tipranavir. When coadministered with ribavirin, its contraindications also apply to this combination regimen (eg, Pregnancy Cat.X).

Warnings/Precautions:
HCV genotype 1a: test for presence of virus with NS5A resistance-associated polymorphisms prior to initiation. Monitor hepatic function prior to initiation, at Week 8, and as clinically indicated; perform additional testing at Week 12 for patients receiving 16 weeks of therapy. Consider discontinuing if ALT persistently >10XULN. Discontinue if ALT elevation is accompanied with liver inflammation or increasing conjugated bilirubin, alkaline phosphatase, or INR. Pregnancy. Nursing mothers.

Interactions:
See Contraindications. Concomitant moderate CYP3A inducers or certain strong CYP3A inhibitors: not recommended. May be antagonized by nafcillin, bosentan, etravirine, modafinil. May be potentiated by ketoconazole, elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate or tenofovir alafenamide. Potentiates tacrolimus (monitor tacrolimus levels, changes in renal function), atorvastatin (limit maximum 20mg/day), rosuvastatin (limit maximum 10mg/day). May potentiate fluvastatin, lovastatin, simvastatin; use lowest effective dose of these drugs.

Pharmacological Class:
HCV NS5A inhibitor + HCV NS3/4A protease inhibitor.

Adverse Reactions:
Fatigue, headache, nausea, diarrhea, anemia.

Note:
For ribavirin specific dosing and safety information, refer to the full prescribing information.

Generic Availability:
NO

How Supplied:
Carton—2 x 14 dose packs